Clinical Trial

Platelet-Rich Plasma for Acute Nonarteritic Anterior Ischemic Optic Neuropathy: A Prospective Randomized Controlled Study

Study acronym: PRP-NAION
Completed
View on ClinicalTrials.gov →
Summary
This prospective randomized clinical study aims to evaluate the efficacy and safety of autologous platelet-rich plasma (PRP) injection in patients with acute non-arteritic anterior ischemic optic neuropathy (NAION). Eligible patients are randomly assigned to receive posterior subtenon PRP injections or to an observation-only control group. The PRP group receives injections at baseline and during follow-up. Comprehensive ophthalmologic evaluations, including best-corrected visual acuity, visual field testing, and retinal nerve fiber layer thickness measurements, are performed at baseline and scheduled follow-up visits. The primary outcomes include changes in visual function and structural optic nerve parameters, as well as the incidence of treatment-related adverse events.
Trial Details
NCT Number NCT07330713
Lead Sponsor Uludag University
Conditions Nonarteritic Anterior Ischemic Optic Neuropathy
Enrollment 31 participants
Start Date 2022-01-01
Primary Completion 2024-01-31 (estimated)
Study Completion 2024-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-09